Hogan Lovells advises Avidea Technologies on acquisition by Vaccitech

Press releases | 21 December 2021

Washington, D.C., 21 December 2021 – Global law firm Hogan Lovells advised U.S.-based biotechnology company Avidea Technologies in the successful closing of its acquisition by Vaccitech Plc. The closing was announced on 13 December.

Vaccitech is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapies and vaccines. As part of the deal, it acquired existing product candidates based on Avidea’s SNAPvax™ platform, aimed at providing a means for effective immunotherapies for oncology.

Read more on the deal here.

The deal is an example of the capabilities offered by Hogan Lovells’ Emerging Companies Practice, which provides businesses in the life sciences and health care industry a range of services from corporate formation through strategic exits.

The Hogan Lovells corporate M&A team was led by partner Kevin Clayton and senior associate Drew Cook (both D.C.). Also providing support for the deal were D.C. partners Tim Lloyd and Meg McIntyre, Northern Virginia partner Kevin Greenslade, and D.C. senior associate David Russo.